Mrna-4157, A Novel Mrna Vaccine, With Pembrolizumab In Melanoma

mRNA-4157, a novel mRNA vaccine, with pembrolizumab in melanoma

3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma

KEYNOTE-942: DMFS findings of a personalized mRNA vaccine in melanoma

Unanswered questions in the use of mRNA-based personalized cancer vaccines

A personalized mRNA vaccine with pembrolizumab in melanoma

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival

New study finds mRNA vaccine helps battle against melanoma

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

European Society for Medical Oncology (ESMO)

Neoantigen Vaccine With Pembrolizumab Has Clear Benefit in Resected Melanoma

Dr. Meredith McKean on mRNA Combined Immunotherapy for Melanoma – NBCLX

Sarah Cannon Research Institute

Dr. Jeffrey Weber Discusses Promising Results of mRNA-Based Melanoma Vaccine Trial

NYU Langone Health

Adding new vaccine type to leading immunotherapy dramatically reduced melanoma recurrence

Can personalized mRNA vaccines be applicable in lung cancer?

Highlights in melanoma at AACR 2023

The future of personalized, neoantigen cancer vaccines

Melanoma study finds mRNA vaccine combined with standard treatment could reduce recurrence

Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma

Highlighting the advantages of neoantigen mRNA vaccines in melanoma

Melanoma mRNA vaccine may improve life span of patients

Advances in utilizing neoadjuvant immunotherapy in melanoma